Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Current Leases (2023 - 2025)

Compass Therapeutics' Current Leases history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Current Leases rose 195.86% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, up 195.86%, while the annual FY2025 figure was $1.0 million, 195.86% up from the prior year.
  • Current Leases for Q4 2025 was $1.0 million at Compass Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.2 million in Q1 2024 and bottomed at $109000.0 in Q1 2025.
  • The 3-year median for Current Leases is $1.0 million (2024), against an average of $852250.0.
  • The largest YoY upside for Current Leases was 195.86% in 2025 against a maximum downside of 91.09% in 2025.
  • A 3-year view of Current Leases shows it stood at $1.2 million in 2023, then crashed by 71.76% to $338000.0 in 2024, then soared by 195.86% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Current Leases are $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $271000.0 (Q2 2025).